The DRAGON 1 trial aims to assess training, implementation, safety and feasibility of combined portal- and hepatic-vein embolization (PVE/HVE) to accelerate future liver remnant (FLR) hypertrophy in patients with borderline resectable colorectal cancer liver metastases.

Dragon 1 Protocol Manuscript: Training, Accreditation, Implementation and Safety Evaluation of Portal and Hepatic Vein Embolization (PVE/HVE) to Accelerate Future Liver Remnant (FLR) Hypertrophy

Aldrighetti, L A;De Cobelli, F;
2022-01-01

Abstract

The DRAGON 1 trial aims to assess training, implementation, safety and feasibility of combined portal- and hepatic-vein embolization (PVE/HVE) to accelerate future liver remnant (FLR) hypertrophy in patients with borderline resectable colorectal cancer liver metastases.
Colorectal cancer liver metastases (CRLM)
Combined portal- and hepatic vein embolization (PVE/HVE)
Future liver remnant (FLR)
Hepatic vein embolization (HVE)
Liver hypertrophy
Portal vein embolization (PVE)
Accreditation
Hepatectomy
Hepatic Veins
Hepatomegaly
Humans
Hypertrophy
Liver
Multicenter Studies as Topic
Portal Vein
Prospective Studies
Treatment Outcome
Embolization, Therapeutic
Liver Neoplasms
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/132512
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 4
social impact